Searchlight
Searchlight provides vital information regarding new therapies and those in the pipeline. It presents relevant and easily digestible information on study results of our own clinical trials, articles on other AIDS-related subjects, commentary from prominent national doctors and scientists, as well coverage of other ARA-related developments.
Current Issue: Winter/Spring 2009 issue of Searchlight
Winter/Spring 2009 An Ounce of Prevention. At Home in New Quarters |
Past Searchlight Issues:
Spring 2008 The Challenge of Emptying The HIV Reservoir HIV Viral Reservoirs: Barriers to a Cure Measuring the HIV Reservoir |
Winter 2007 Immunotherapies - Strengthening the Body's Own Defenses Therapeutic Vaccines: An Alternative Strategy to Contain HIV Infection Immunotherapies For HIV |
Fall 2006 HIV PREVENTION RESEARCH TIED DOWN BY CONTROVERSY Are We Ready For PrEP? The Logic Behind Treatment Recommendations for the Newly Infected |
Spring 2006 VACCINE ISSUE Still Shooting in the Dark? How Does the US Fund HIV Vaccine Research? |
Winter 2005 MICROBICIDES ISSUE Microbicides Offer Hope as HIV Prevention Tools That Are Under Individual Control Viral Load Measurements: The Log Scale |
Spring 2005 Highlights from the 12th Conference on Retroviruses and Opportunistic Infections ARA's Director of Scientific Communications Marjan Hezareh, Ph.D. reviews the latest scientific, therapeutic and clinical data presented at the 12th Conference on Retroviruses and Opportunistic Infections, held in Boston, Massachusetts in Februarry, 2005. Metabolic Disorders Secondary to HIV Infection and Antiretroviral Treatment - Part II ARA's Medical Director Stephen J. Brown, M.D. reviews some of the latest studies and recommendations to prevent and treat HIV-related metabolic disorders, including lipodystrophy, in this second installment of a two-part series. We provide an update on our progress in developing the antiviral prostratin. |
Fall 2004 Highlights from the XVth International AIDS Conference in Bangkok ARA's Medical Director Stephen J. Brown, M.D. reviews in this short report the latest scientific, therapeutic and clinical data presented at the XVth International AIDS Conference (July, 2004) held in Bangkok, Thailand. Is Injectable Silicone a Safe and Effective Treatment of HIV-associated Facial Lipoatrophy? ARA's Director of Scientific Communications Marjan Hezareh, Ph.D. reviews and compares various treatment options for the correction of facial lipoatrophy to the latest results obtained on the safety and efficacy of treatment with microdroplet silicone injections. We provide an update on our progress in developing the antiviral prostratin. |
Spring 2004 Metabolic Disorders Associated with HIV and its Treatment Part I: Lipodystrophy, Etiology, Relationship to HAART and HAART Regimen Considerations ARA's Medical Director Stephen J. Brown, M.D. discusses HIV-related lipodystrophy, excercise specialist Noah Manne discusses the importance of diet and exercise for the immune-compromised, and ARA's Director of Scientific Communications Marjan Hezareh, Ph.D. takes a look at some of the briefs from the 11th Conference on Retroviruses and Opportunistic Infections. A new study being conducted at ARA is also announced. We provide an update on our progress in developing the antiviral prostratin. |
Summer 2003 HIV-related Peripheral Neuropathy: Diagnosis and Treatment Noted neurologist and member of ARA's Institutional Review Board Seymour Young, M.D. discusses HIV-related peripheral neuropathy. ARA's Director of Scientific Communications Marjan Hezareh, Ph.D. looks at results in some recent HIV/AIDS studies. Four new studies being conducted at ARA are also announced. We provide an update on our progress in developing the antiviral prostratin. |
Spring 2003 New and Promising Drugs in Devlopment Versus Rising Number of New HIV Infections in U.S. ARA's Director of Scientific Communications discusses information from the 10th Conference on Retroviruses and Opportunistic Infections In Boston. Marjan also looks at “RNA Interference: A New Tool in the Fight against HIV/AIDS.” Thrree new studies to be conducted at ARA are announced. We provide an update on our progress in developing the antiviral prostratin. |
Fall 2002 HIV RESERVOIR ISSUE HIV-1: The Nature of Viral Reservoirs Robert Siliciano of John Hopkins University discusses the significance of viral reservoirs in eradicating HIV and assesses the likelihood of cleaning out or "flushing" these reservoirs. ARA's Searchlight Editor Marjan Hezareh discusses reservoirs and also gives us her report on the 2002 XIV International AIDS Conference in Barcelona. We provide an update on our progress in developing the antiviral prostratin. |
Spring 2002 HIV OVERVIEW ISSUE HIV-1: Two Decades of Clinical and Scientific Advances ARA's Searchlight Editor Marjan Hezareh, Ph.D. looks at twenty years of HIV/AIDS research and drug development, assesses where we are now, and takes a look at some new antiviral drugs in the pipeline. |
Fall 2001 VACCINE & PREVENTION ISSUE A Boosted Hope: AIDS Vaccine Research ARA's new Director of Scientific Communications and Searchlight Editor Marjan Hezareh, Ph.D. looks at the challenges faced by the scientific community in developing an effective HIV/AIDS vaccine. Marjan also reports on vaccine developments reported at the March Keystone Conference and the recent "AIDS Vaccine 2000" Symposium in Philadelphia. |
Spring 2001 Prostratin: A Potential Adjuvant Therapy for HAART Against HIV-1 Reservoirs ARA's Director of Clinical Research looks at the unique anti-HIV properties of prostratin, a compound derived from a plant native to Western Samoa. |
Fall 2000 Achy Breaky HAART Structured Treatment Interruptions (STIs) are discussed by Linda Grinberg, President of the Foundation for AIDS & Immune Research and a member of the Board of Directors of Project Inform. |
Spring 2000 AVN, a Potentially Serious Bone Disorder— |
Winter 1999/2000 HIV Vaccine Development— |
Fall 1999 Natural immunity to HIV? Understanding the reasons why some individuals exposed to HIV remain uninfected should shed light on the nature of protective immunity against HIV. Drug Resistance Profiles in Tissues Study Results presented at the 3rd International Workshop on HIV Drug Resistance and Treatment Strategies in San Diego. |
Summer 1999 Acupuncture for Treating Neuropathy Making sense of the science: acupuncture therapy was recently evaluated in a large, randomized placebo-controlled clinical trial. HIV Neuropathies Several disorders, no proven treatments. |
Spring 1999 Mucosal biopsy study results presented in Chicago AIDS Research Alliance collaborative effort bears fruit Abstract presented at the 6th Conference on Retroviruses and Opportunistic Infection in Chicago. Is Sterilizing Immunity Necessary to Prevent HIV Disease?— Interview with Bob Gallo Dr. Robert Gallo is co-discoverer of the HIV virus and Director of the Institute of Human Virology in Baltimore, MD. Is Sterilizing Immunity Necessary to Prevent HIV Disease?— Interview with Neal Nathanson Dr. Neal Nathanson is the Director of the Office of AIDS Research, the office responsible for setting the scientific agenda for AIDS research at the National Institutes of Health. |
Winter 1998/1999 The Gut Reaction to HIV Gut tissue is uniquely vulnerable to HIV, and careful investigation of the gut is likely to provide valuable clues to the pathology underlying HIV infection. XQ-9302 Study Report Report on a Phase I/II study evaluating a compound comprised of twenty uncharacterized Chinese botanicals in HIV-1 infected individuals. |
Summer/Fall 1998 Clinical Trials to Clinical Reality "Bridging the gap" between science and the patient. |
